Healthcare Business Review: Nu Skin’s Possible China Problem, Sucampo and Takeda Win With FDA

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of Nu Skin Enterprises Inc. (NYSE:NUS) slide on rumors that it might lose its license in China. If the chatter turns out to be correct, Usana Health Sciences, Inc. (NASDAQ:USNA) would likely be pulled down as well according to Citron Research, who says that the latter has endured as many if not more “China issues” than has Nu Skin.

Don’t Miss: Will Cable Kill the Console?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Takeda Pharma (TKPYY.PK) report that the FDA has granted the status of priority review to their supplemental new drug application for an additional indication for Amitiza, which is a treatment for opioid-induced constipation in patients suffering from chronic, non-cancer pain. A ruling is expected by late January 2013.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business